Sudeep Pharma FY26 Revenue Up 28% to ₹642.3 Crore; Invests in Battery Materials Plant
Sudeep Pharma's FY26 revenue increased by 28% to ₹642.3 crore. The company acquired an 85% stake in Nutrition Supplies Services (NSS). A groundbreaking ceremony was held for a Battery Materials Plant at Dahej on 23 January 2026, with commissioning targeted for early CY2027. Q4FY26 revenue stood at ₹182.3 crore, a 16% YoY growth. The company appointed a new business head for NSS.
The announcement details significant financial growth, strategic acquisitions, and expansion into new markets, suggesting a high impact on the company's future performance and market position.
The announcement highlights strong financial performance with increased revenue and strategic acquisitions, indicating positive growth and expansion for the company.
Sudeep Pharma Limited announced its Q4FY26 and FY26 results, highlighted by a 28% increase in revenue to ₹642.3 crore for FY26. The company's MD noted that FY26 was transformative, marked by the successful listing of Sudeep Pharma Limited. During the year, Sudeep Pharma B.V., a wholly-owned subsidiary, acquired an 85% stake in Nutrition Supplies Services (NSS), enhancing advanced formulation capabilities and expanding customer reach, particularly in the European market. NSS has started contributing to the revenue from 22nd May 2025. The integration process is progressing smoothly and is expected to further enhance the Nutrition business and regulated market presence. 22nd May 2025 is when NSS has started contributing to the revenue. Groundbreaking ceremony for the Battery Materials Plant at Dahej under Sudeep Advanced Materials (SAM) focused on battery-grade iron phosphate for LFP batteries and targeted for commissioning in early CY2027. During Q4FY26, the business witnessed temporary disruptions arising from gas supply issues, sharp increases in sulphuric and phosphoric acid prices, and supply chain disruptions due to the West Asia conflict. Revenue from operations for Q4FY26 stood at ₹182.3 crore, registering a growth of 16% year-over-year. The company has appointed a new business head for NSS, and the integration process is progressing smoothly with encouraging operational and customer synergies.
The greenfield project at Nandesari is progressing well and has completed Internal Validation and Qualification Process. The company successfully conducted the groundbreaking ceremony for the Battery Materials Plant at Dahej on 23 January 2026 with a project cost of approximately ₹300 crore. This facility will have an initial capacity of 25,000 MT, with an expected completion by March 2027. The company has set a target of 100,000 MT by 2030. The company has expanded its presence in Peru, while its existing markets in the US and Europe are also witnessing encouraging traction and improving customer engagement.
Mr. Sujit Bhayani, Managing Director, stated that the company reported a strong year, marked by strategic milestones and their highest-ever revenue. He also mentioned witnessing growing engagement from global OEMs, cell manufacturers, and cathode players as supply chains diversify beyond China. During the quarter, they received qualification orders from Korean customers and a 500 MT purchase order from a leading listed player in India, reflecting encouraging early traction for their advanced materials business.
What to do with a filing like this
Sudeep Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudeep Pharma Limited. Read the original for the full detail.